[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tehran University of Medical Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":225},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,72,101,124,152,176,198],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100616459","phase-3-comparison-of-intranasal-ketorolac-and-intranasal-ketamine-in-digital-nerve-block-pain-100616459",false,"NCT07305883","Comparison of Intranasal Ketorolac and Intranasal Ketamine in Digital Nerve Block Pain","Intranasal Ketorolac Effectiveness In Comparison To Intranasal Ketamine for Digital Nerve Block Pain; A Randomized, Double Blind Trial","Inclusion Criteria:\n\n* Age: 18-65 years\n* Weight \\> 50 kg\n* Requires digital nerve block\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Active peptic ulcer disease (PUD)\n* History of hypersensitivity to NSAIDs\n* Pregnancy and breastfeeding\n* Renal failure\n* Hepatic failure\n* Patients who have received analgesics within the past 6 hours\n* Nasal congestion\n* Upper respiratory tract infection\n* Patients with a history of kidney transplantation\n* Active gastrointestinal bleeding\n* Systolic blood pressure less than 90 mmHg or greater than 180 mmHg\n* Heart rate less than 50 per minute or greater than 150 per minute\n* Concurrent use of NSAIDs or anticoagulant drugs\n* Inability to provide informed consent\n* Anatomical abnormalities of the nose or skull base (congenital or acquired)\n* Hyperreactive airway disease such as severe asthma\n* Coagulation disorders\n* Intracranial hemorrhage\n* Suspected aortic dissection\n* Suspected rupture of abdominal aortic aneurysm\n* History of gastrointestinal perforation\n* Gastrointestinal bleeding within the past month","ALL","18 Years","65 Years",{"count":20,"type":21},64,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study aims to compare the analgesic effectiveness and side effects of intranasal ketorolac versus intranasal ketamine for reducing pain prior to digital nerve block procedures in patients with finger injuries in emergency department.",[27,28],"Pain","Digital Block","NOT_YET_RECRUITING","2025-12-13",{"date":32,"type":33},"2025-12-26","ACTUAL",{"date":35,"type":21},"2025-12-28",{"date":37,"type":21},"2026-08-01",{"name":39,"class":40},"Tehran University of Medical Sciences","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100589787","evaluating-the-efficacy-of-digestive-aid-in-functional-dyspepsia-100589787","NCT06958952","Evaluating the Efficacy of \"Digestive Aid\" in Functional Dyspepsia","Evaluating the Efficacy of \"Digestive Aid\" in Functional Dyspepsia: A Randomized Double Blind Control Trial","Efficacy","Inclusion Criteria:\n\n* The new onset dyspeptic patients\n\nExclusion Criteria:\n\n* Participants with co-morbidities (known GI diseases)\n* Taking medications,\n* Those with abnormal gastrointestinal findings in physical examination and para-clinical investigations","75 Years",{"count":51,"type":21},50,[53],"NA","Functional Dyspepsia (FD) is diagnosed in the presence of bothersome epigastric pain or burning, early satiation and\u002For postprandial fullness of greater than 8 weeks duration, in the absence of alarm signs. Alarm signs include weight loss, gastrointestinal bleeding, anemia, dysphagia, and family history of upper gastrointestinal malignancies. FD is a common gastrointestinal complaint. It's prevalence in Iranian population is reported to be from 2.2% to 29.9% (1). FD should be introduced as a disorder of gut-brain interaction (DGBI), together with a simple account of the gut-brain axis and how this is impacted by diet, stress, cognitive, behavioral and emotional responses to symptoms and post-infective changes. Histamine-2-receptor antagonists, proton pump inhibitors, and prokinetics are introduced as the first line classic treatment in FD. (2) Tricyclic antidepressants (TCAs) used as gut-brain neuromodulators are an efficacious second-line treatment for FD. (2) Antipsychotics, such as sulpiride 100 mg four times a day or levosulpiride 25 mg three times a day, may be efficacious as a second-line treatment for FD. Tandospirone, Pregabalin, Mirtazapine are among the suggested second line pharmachological therapy. (2) FD expresses a spectrum of various upper gastrointestinal complaints. Epigastric pain, retrosternal pain, regurgitation, nausea, vomiting, belching, dysphagia, and early satiety are among the most frequent symptoms. Therefore, a combination of medications might be needed to alleviate the patients' discomfort. The pharmaceutics have proposed the package of medications to increase the patient compliance. \"Digestive Aid\" is a cocktail that contains Marshmallow, Ginger, Gentian, Fennel, Peppermint, and Anise oil. It is widely used by physicians to control dyspeptic symptoms. There are studies on human and animals that showed the efficacy of mentioned herbal supplements on dyspepsia. To the best of our knowledge there is no study about the efficacy of \"Digestive Aid\" in the dyspeptic patients. This trial is conducted to evaluate the efficacy of mentioned product in alleviating the symptoms in FD in a sample of the Iranian patients.",[56],"Dyspepsia Chronic",[47,58,59,60,61],"Clinical trial","Functional Dyspepsia","questionnaire","Digestive Aid","RECRUITING","2025-04-27",{"date":65,"type":33},"2025-05-06",{"date":67,"type":33},"2025-04-15",{"date":69,"type":21},"2026-03",{"name":39,"class":40},1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":71},"100558736","phase-3-debiri-plus-chemotherapy-vs-chemotherapy-alone-in-colorectal-cancer-liver-metastases-100558736","NCT06555003","DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases","Comparative Analysis of the Efficacy of Irinotecan-loaded Drug-eluting Beads (DEBIRI) in Combination With Systemic Chemotherapy Versus Chemotherapy Alone in Unresectable Colorectal Cancer Liver Metastases: a Randomized Clinical Trial","CLEAR-DEBIRI","Inclusion Criteria:\n\n* unresectable\u002Fborderline resectable colorectal cancer liver metastases, chemotherapy-naïve for metastatic disease, Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less adequate hematologic, hepatic, and renal function ( absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL, platelet ≥ 75 ×10\\^9\u002FL, international normalized ratio ≤ 1.3, Total bilirubin ≤ 2.0 mg\u002FdL, aspartate aminotransferase and alanine aminotransferase ≤ 5 × the upper limit of normal (ULN), Albumin ≥ 2.5 g\u002FdL, Creatinine ≤ 2.0 mg\u002FdL)\n\nExclusion Criteria:\n\n* candidates for curative surgery without the need for neoadjuvant therapy, Liver involvement of ≥ 70%, brain metastases or Peritoneal carcinomatosis, cirrhosis, presence or History of an allergic reaction to any of the study drugs Chronic viral hepatitis B or C",{"count":81,"type":21},116,[24],"A total of 116 patients who meet the inclusion criteria and are chemotherapy-naïve for their metastatic disease, will be randomly assigned to either the treatment group (DEBIRI plus systemic chemotherapy) or the control group (systemic chemotherapy alone).\n\nAfter 4 cycles of chemotherapy and 2 cycles of DEBIRI, patient reassessment to evaluate treatment response, based on RECIST criteria, will be performed using MRI or CT scan within 1-3 months of treatment initiation.\n\nThe feasibility of secondary tumor resection, as primary endpoint, will be reassessed at a three-month follow-up multidisciplinary team (MDT) meeting, guided by established clinical guidelines.",[85,86],"Liver Neoplasm","Colorectal Cancer Metastatic",[88,89,90,91,92],"irinotecan loaded drug-eluting beads TACE (DEBIRI-TACE)","colorectal liver metastases","survival","irinotecan","chemoembolization","2025-04-17",{"date":95,"type":33},"2025-04-23",{"date":97,"type":33},"2025-01-20",{"date":99,"type":21},"2027-12",{"name":39,"class":40},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":108,"minAge":17,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100571516","iodine-supplementation-and-fertility-parameters-100571516","NCT06721273","Iodine Supplementation and Fertility Parameters","The Effect of Iodine Supplementation on Fertility Parameters in Women Experiencing Infertility","Inclusion Criteria:\n\n* Women with diminished ovarian reserve\n* Willingness to participate\n* Age range: 18 to 45 years\n* Women with a menstrual cycle of 21 to 42 days\n* Women who have not used any contraceptive methods in the past 12 months\n* Women who have not had in sexual intercourse for more than 2 months\n\nExclusion Criteria:\n\n* Unwillingness to participate\n* Women with polycystic ovary syndrome or endometriosis\n* Diagnosis of any thyroid disease\n* Use of any medication that affects the thyroid function\n* Use of dietary supplements containing iodine (excluding those considered in the present study)\n* Use of iodine-containing disinfectants","FEMALE","45 Years",{"count":111,"type":21},230,[53],"Iodine has been identified as a potential factor influencing female fertility during the childbearing years. The American Thyroid Association recommends that women attempting to conceive take a supplement containing 150 µg of iodine. However, no clinical trials have specifically examined the necessity of iodine supplementation in women experiencing infertility. Furthermore, no information is available on the optimal dose and duration of iodine supplementation to increase the chances of successful treatment in this group of women. Therefore, this study aims to investigate the effects of iodine supplementation on fertility parameters in infertile women.",[115],"Infertility (IVF Patients)","2024-12-03",{"date":118,"type":33},"2024-12-06",{"date":120,"type":21},"2025-03-01",{"date":122,"type":21},"2027-03-01",{"name":39,"class":40},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":139,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":71},"100563420","effects-of-aerobic-and-resistance-exercises-on-inpatients-liver-transplantation-recipients-100563420","NCT06615934","Effects of Aerobic and Resistance Exercises on Inpatients Liver Transplantation Recipients","Comparing the Effects of Aerobic and Resistance Exercises With Routine Physiotherapy in Inpatients Immediately After Liver Transplantation on Muscle Strength, Functional and Aerobic Capacity, and Blood Biomarkers","Inclusion Criteria:\n\n1. Patients who undergo elective surgery after the approval of the liver transplant commission.\n2. Having an underlying liver disease with metabolic disorder (as determined by the Liver Transplantation Commission)\n3. Absence of transplantation of other organs\n4. No re-transplantation of the liver\n5. Age more than 18 years\n6. Ability to participate in initial evaluations\n7. Patient's ability to understand questionnaire questions\n\nExclusion Criteria:\n\n1. The patient's lack of satisfaction with continuing cooperation for any reason\n2. Re-transplantation up to 3 months after discharge\n3. Facing the patient with early allograft dysfunction or primary nonfunction\n4. Encountering the criteria of non-implementation of the intervention during 50% of the days of stay in the hospital or more\n5. Patients with Postoperative respiratory failure (Extubation \\> 48 hours)",{"count":132,"type":21},40,[53],"The prevalence of chronic liver disease and primary liver cancer is still increasing on a global scale, and so are their associated deaths.\n\nCompared to other diseases, death from liver disease often means premature death, because two-thirds of the lives lost are working years.\n\nLiver transplantation (LT) is an important and life-saving treatment option for the treatment of congenital metabolic disorders, acute liver failure, end-stage chronic liver disease (ESLD) and primary liver cancers.\n\nModern liver transplantation is characterized by significant improvements in post-transplant patient survival, graft survival, and quality of life.\n\nImpaired physical fitness of patients with end-stage liver disease often persists after liver transplantation and compromises post-transplant recovery.\n\nPrior to liver transplantation, excess ammonia taken up by skeletal muscle is a major metabolic driver of muscle wasting in end-stage liver disease and mainly inhibits the mTOR signaling pathway that supports muscle protein synthesis.\n\nBecause excess ammonia is no longer present after transplantation, recovery of muscle mass and function can be expected in patients. However, immunosuppression with calcineurin inhibitors that inhibit the mTOR signaling pathway may improve lethal length.\n\nIt is also thought that post-transplant treatment regimens contribute to delayed recovery of decreased bone mineral density and increased fracture risk.\n\nGreater muscle mass, as measured by creatinine clearance at 1 year after transplantation, was associated with longer recipient and allograft survival.\n\nThe results of previous studies indicate low cardiovascular fitness in patients after liver transplantation.\n\nSince after liver transplantation, cardiovascular diseases cause 19 to 42% of deaths not related to the liver, performing aerobic exercises to obtain and maintain cardiovascular fitness after liver transplantation can reduce the mortality rate. After transplanting, reduced significantly.\n\nConsidering the important role of the immune system in transplant rejection, the safety of sports training is very important in terms of not over-activating the immune system and endangering the life of the transplanted tissue. In previous studies related to exercise and immune system activity and inflammatory cytokines after transplantation, it has been shown that moderate exercise including aerobic and resistance exercises can inhibit inflammatory cytokines and have beneficial effects on the immune system.\n\nHigh levels of tumor necrosis factor-alpha (TNF-α) in the period after transplant surgery are associated with an increased risk of transplant rejection.\n\nAerobic exercise reduces levels of inflammatory cytokine TNF-α and markers of liver function in patients with chronic liver diseases.\n\nAccording to this evidence, it seems that doing sports exercises is effective in reducing the risk of transplant rejection and modulating the patient's immune system. Acute graft rejection occurs days to weeks after transplantation. The immune system can see the transplanted organ as foreign and attack it, destroy it and lead to transplant rejection.\n\nConsidering the mentioned benefits of exercise therapy after liver transplantation, it is possible that the early start of exercise therapy in the hospitalization phase leads to a reduction in the risk of transplant rejection and improvement of allograft residues in patients after liver transplantation.\n\nConsidering that the current evidence shows that there is no use of a specific rehabilitation protocol in the hospitalization phase of patients after liver transplantation, we intend to evaluate its effects with changes in the common physiotherapy program in these departments according to the specific conditions of these patients. In other words, despite the acceptable therapeutic effects, the use of a combined protocol of aerobic and resistance exercises in the hospitalization phase of these patients has not been reported so far.",[136,137,138],"Liver Transplant Disorder","Liver Transplant; Complications","End-stage Liver Disease",[140,141,142,143],"physiotherapy","aerobic exercise","resistance exercise","liver transplant recipients","2024-09-26",{"date":146,"type":33},"2024-09-27",{"date":148,"type":21},"2024-10-01",{"date":150,"type":21},"2025-01-15",{"name":39,"class":40},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":4},"100559785","phase-2-human-placenta-mesenchymal-stem-cells-derived-exosomes-injection-for-treatment-of-complex-anal-fistula-100559785","NCT06568653","Human Placenta Mesenchymal Stem Cells Derived Exosomes Injection for Treatment of Complex Anal Fistula","The Efficacy of Human Placenta Mesenchymal Stem Cells Derived Exosomes Injection for Treatment of Complex Anal Fistula in Colorectal Surgery Department of Imam Khomeini Hospital Complex: A Non-randomized Clinical Trial.","Inclusion Criteria:\n\n* participants with complex perianal fistula\n* provided written informed consent\n\nExclusion Criteria:\n\n* participants with any inflammatory bowel diseases\n* pregnant or lactating participants\n* participants with contraindications for surgery\n* participants with hepatitis\n* participants with uncontrolled diabetes\n* participants with alcohol or substance abuse","70 Years",{"count":132,"type":21},[162],"PHASE2","The goal of this clinical trial is to learn if human placenta mesenchymal stem cells (MSC)-derived exosomes work to treat complex perianal fistula in adults without Crohn's disease. The safety of this treatment will also be learned. The main questions it aims to answer are:\n\n* Does treatment with MSC-derived exosomes lower the number of fistula recurrences in participants?\n* Is treatment with MSC-derived exosomes safe? We will compare treatment with MSC-derived exosomes to the routine treatment which is fistulotomy (surgery to close the fistula) alone to see if MSC-derived exosomes work better to treat complex fistula.\n\nParticipants will:\n\n* Undergo fistulotomy plus MSC-derived exosome injections or fistulotomy alone.\n* Visit the clinic the week after surgery and then every 4 weeks for checkups and tests",[165],"Fistula Perianal",[167],"fistula, perianal fistula, non-Crohn's disease, exosome, mesenchymal stem cell, human placenta stem cell","2024-08-22",{"date":170,"type":33},"2024-08-23",{"date":172,"type":21},"2024-09-15",{"date":174,"type":21},"2025-02-15",{"name":39,"class":40},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":71},"100557330","phase-1-effects-of-exosome-adminstration-in-preventing-early-leakage-in-rectal-cancer-patients-undergoing-low-anterior-resection-100557330","NCT06536712","Effects of Exosome Adminstration in Preventing Early Leakage in Rectal Cancer Patients Undergoing Low Anterior Resection","Investigating the Effect of Intraperitoneal Administration of Exosome in Preventing Early Anastomotic Leakage in Rectal Cancer Patients Who Undergo Low Anterior Resection","Inclusion Criteria:\n\n-Patients with Stage II-III rectal cancer who underwent neoadjuvant chemoradiation therapy and are candidates for low anterior resection surgery\n\nExclusion Criteria:\n\n* Patients who need emergency surgery (presenting with peritonitis or signs of obstruction)\n* Patients with apparent malnutrition or patients who have serum albumin levels of less than 3 g\u002Fdl\n* Patients who receive corticosteroids ( an equivalent dose of prednisolone 5 mg\u002Fday or more)\n* Patients with chronic pulmonary disease\n* Patients who need more than two units of blood transfusion perioperatively",{"count":184,"type":21},20,[186],"PHASE1","The goal of this clinical trial is to assess the safety and efficacy of Human Placenta Mesenchymal Stem Cells Derived Exosomes in preventing early anastomosis leak in patients undergoing low anterior resection for rectal cancer. The main question it aims to answer are\n\nDo Mesenchymal Stem Cell-Derived Exosomes prevent early anastomosis leak in patients undergoing low anterior resection for rectal cancer?\n\nIf there is a comparison group: Researchers will compare Mesenchymal Stem Cells Derived Exosomes to placebo to see if it can prevent early anastomotic leakage.\n\nParticipants will receive intraperitoneal Mesenchymal Stem Cells Derived Exosomes at the end of their surgery.",[189],"Rectal Cancer","2024-08-02",{"date":192,"type":33},"2024-08-05",{"date":194,"type":21},"2024-08",{"date":196,"type":21},"2024-12",{"name":39,"class":40},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":205,"sex":108,"minAge":17,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":71},"100426317","phase-2-clinical-response-and-toxicity-of-hypo-fractionated-chemoradiotherapy-in-cervix-cancer-100426317","NCT04831437","Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer","Comparison of Clinical Response and Toxicity of Hypo-fractionated Chemoradiation With Standard Treatment in Patients With Uterine Cervix Cancer","Inclusion Criteria:\n\n* Pathology of squamous cell carcinoma (SCC), adenocarcinoma, adenosquamous carcinoma of uterine cervix- International Federation of Gynecology and Obstetrics (FIGO) stage IB, IIA, IIB, IIIA, IIIB (due to hydronephrosis without creatinine clearance compromise), IIIC1 (if less than 3 lymph nodes with size less than 3cm, and without involvement of common iliac chain)- Patient eligible for definitive chemoradiotherapy followed by brachytherapy\n\nExclusion Criteria:\n\n* Creatinine clearance less than 30ml\u002Fmin, any histology other than the above, requirement of paraaortic lymph node irradiation, inflammatory bowel disease, connective tissue disorders, previous pelvic radiotherapy, FIGO stage IA or IV, Eastern Cooperative Oncology Group (ECOG) performance status greater than 2, History of previous hysterectomy",true,"85 Years",{"count":208,"type":21},60,[162],"Uterine cervix cancer can be treated definitively with concurrent chemoradiation (external beam radiotherapy and chemotherapy) followed by high dose rate brachytherapy. Treatment duration can be shortened by increasing the dose per fraction of treatment which can reduce costs and patient exposure. The aim of our study is to determine the non-inferiority of hypofractionated radiotherapy compared with conventional treatment.",[212],"Cervix Uteri Cancer",[214,215,216],"Hypofractionation","Chemoradiation","Brachytherapy","2021-10-11",{"date":219,"type":33},"2021-10-12",{"date":221,"type":33},"2021-04-01",{"date":223,"type":21},"2028-03",{"name":39,"class":40},""]